Abstract: A combination product comprising a carbapenem and a compound of formula (I?), or a pharmaceutically acceptable salt thereof: a pharmaceutical composition comprising the combination product; and methods of treating bacterial or fungal infections using the combination product and pharmaceutical composition.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: The present invention provides stable antimicrobial and disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The invention also provides on-demand storage and mixing vessels and methods for preparing and delivering on demand formulations. In addition, the invention provides antiviral, antibiotic and general antimicrobial uses, in vivo, on surfaces and via spray applications.

Abstract: The present invention provides new storable and stable disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The component in the device is devoid of stability issues, since the solid precursors are instantly to be dissolved in a pharmaceutically-acceptable diluent, adjuvant, or carrier, and combined with an activator (e.g. acetic acid or its salts), optionally combined with a viscosity enhancer, optionally combined with a dye. The main product is generated by breaking or opening seals, barriers or ports between an optional number of compartments in a multi-compartment device to mix the contents in the compartments, followed by gently squeezing or shaking the device to generate the disinfectant solution, wherein the resulting solutions can be taken out through a cap, port or opening on the multi-compartment device.

Abstract: A combination product comprising a carbapenem and a compound of formula (I?), or a pharmaceutically acceptable salt thereof: a pharmaceutical composition comprising the combination product; and methods of treating bacterial or fungal infections using the combination product and pharmaceutical composition.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: Q?L-W]X??(I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: Compounds of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: The invention provides compounds of general formula (I?), and their pharmaceutically acceptable salts: wherein: Z is a group having the formula: -T-S-A-Y in which: T is a group selected from —O—, —NH—, —S—, —(XCR7R8)— (where R7 and R8 is independently —H or C1-3 alkyl and X is selected from from —O—, —NH—, —S—); S is —(C?O)—, —(SO2)—, —(PO2)—; A, —O—, —NH—, —S— or —NH(CO)—, —(CR7R8X)— (where R7 and R8 is independently —H or C1-3 alkyl and X is selected from from —O—, —NH—, —S—), -T-S-A- is a group susceptible to hydrolytic and/or enzymatic cleavage in vivo to leave a group selected from —OH, —NH2, —SH, —COOH, —CONH2, —O—(CR7R8)—COOH and —(CR7R8)—CONH2; Y is one or more targeting groups or a lipophilic or hydrophilic group affecting the solubility in water and the biodistribution in a living organism or a living cell; R1-R6 are independently selected from hydrogen, halogen (e.g. F, Cl, Br, I), lower alkyl (e.g.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: Compounds according to formula I are provided: A-L-B wherein A represents a lipophilic chelating moiety which is selective for Zn2+ ions; L is a covalent bond or a linker; and B is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-?-lactamase or DD-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. A method of treating and/or preventing a bacterial infection in a human or non-human mammal employing such compounds are also provided. In such a method, the compound of formula I may be administered in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic.

Abstract: Novel phenazine derivatives, methods for their preparation and their medical use, in particular as anti-neoplastic agents and anti-infective agents, are provided. Novel methods for the preparation of iodinin and myxin are also provided.

Abstract: Novel phenazine derivatives, methods for their preparation and their medical use, in particular as anti-neoplastic agents and anti-infective agents, are provided. Novel methods for the preparation of iodinin and myxin are also provided.

Abstract: Compounds according to formula I are provided: A-L-B wherein A represents a lipophilic chelating moiety which is selective for Zn2+ions; L is a covalent bond or a linker; and B is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-?-lactamase or DD-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. A method of treating and/or preventing a bacterial infection in a human or non-human mammal employing such compounds are also provided. In such a method, the compound of formula I may be administered in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic.

Abstract: A peptide which can adopt a 310-helical conformation in which the side chains of two amino acid residues in the peptide backbone are linked by a group comprising an aromatic 5-membered ring.

Abstract: A peptide which can adopt a 310-helical conformation in which the side chains of two amino acid residues in the peptide backbone are linked by a group comprising an aromatic 5-membered ring.

Abstract: Ultrasound contrast agents comprising microbubbles of biocompatible gas, e.g. a sulphur halide or a perfluorocarbon, stabilized by opsonisable amphiphilic material, e.g. a membrane-forming lipid such as a phospholipid, especially a negatively charged phospholipid such as a phosphatidylserine, may exhibit prolonged contrast-generating residence time in the liver following intravenous administration.

Abstract: The present invention provides the use of an LXR antagonist, or a physiologically-acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is a compound being an ester or carbamate of a hydroxycholesterol, a pharmaceutical composition of such a compound or its use in therapy.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia and to compounds for use as MR contrast agents in the method.

Abstract: The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.